Trial reportIntensive care medicine2011
High-dose selenium reduces ventilator-associated pneumonia and illness severity in critically ill patients with systemic inflammation.
Trial report in Intensive care medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 37 papers, 10 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Micronutrient Deficiencies in Children and Infants With Congenital Heart Diseases (CHD) Admitted for Cardiac Surgery: A Proof-of-concept Study
The Effect of High Dose of Vitamin C on the Clinical Outcome of Mechanically Ventilated Patients Following Sepsis in Intensive Care Unit
Who cites it
37 citing papers in PubMed, 10 syntheses or guidelines pooled it, 122 citations in OpenAlex.
- The Effect of Parenteral Selenium Therapy on Serum Concentration of Inflammatory Mediators: a Systematic Review and Dose-Response Meta-Analysis of Randomized Clinical Trials.Biological trace element research · 2024Pooled it
- The effect of selenium therapy in critically ill patients: an umbrella review of systematic reviews and meta-analysis of randomized controlled trials.European journal of medical research · 2023Pooled it
- The clinical outcomes of selenium supplementation on critically ill patients: A meta-analysis of randomized controlled trials.Medicine · 2019Pooled it
- A meta-analysis of randomized controlled trials: Efficacy of selenium treatment for sepsis.Medicine · 2019Pooled it
- High-dose intravenous selenium does not improve clinical outcomes in the critically ill: a systematic review and meta-analysis.Critical care (London, England) · 2016Pooled it
- Parenteral trace element provision: recent clinical research and practical conclusions.European journal of clinical nutrition · 2016Pooled it
- Selenium supplementation for critically ill adults.The Cochrane database of systematic reviews · 2015Pooled it
- Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012.Intensive care medicine · 2013Guideline
- Effect of parenteral selenium supplementation in critically ill patients: a systematic review and meta-analysis.PloS one · 2013Pooled it
- Antioxidant micronutrients in the critically ill: a systematic review and meta-analysis.Critical care (London, England) · 2012Pooled it
- Effect of Multi-trace Elements Supplementation on Biochemical Markers and Postoperative Outcome in Patients Undergoing Elective Cardiac Surgery.Recent advances in inflammation & allergy drug discovery · 2025Trial
- Trial
- Trial
- Perioperative Oxidative Stress and Sepsis: Pathophysiological and Clinical Implications.Cureus · 2025Review
- Treatment effect of intravenous high-dose selenium in sepsis phenotypes: a retrospective analysis of a large multicenter randomized controlled trial.Journal of intensive care · 2025Article
- GPX3 Overexpression Ameliorates Cardiac Injury Post Myocardial Infarction Through Activating LSD1/Hif1α Axis.Journal of cellular and molecular medicine · 2025Article
- Analysis of the dynamic changes in gut microbiota in patients with different severity in sepsis.BMC infectious diseases · 2023Observational
- Preventative and therapeutic potential of animal milk components against COVID-19: A comprehensive review.Food science & nutrition · 2023Article
- Selenium and mercury concentrations in biological samples from patients with COVID-19.Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) · 2022Article
- Thyroid Dysfunction and COVID-19: The Emerging Role of Selenium in This Intermingled Relationship.International journal of environmental research and public health · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo confirm the pharmacodynamics and evaluate the efficacy of high-dose selenium (Se) administered by continuous infusion, following an initial loading bolus of selenite, on clinical outcome in critically ill patients with systemic inflammatory response syndrome (SIRS).
methodsProspective, placebo-controlled, randomized, single-blinded phase II study in a multidisciplinary university hospital intensive care unit (ICU). Two groups of patients with SIRS, age >18 years, and Acute Physiology and Chronic Health Evaluation (APACHE) II ≥15 (n = 35) were randomized to receive either placebo or intravenous selenite as a bolus-loading dose of 2,000 μg Se followed by continuous infusion of 1,600 μg Se per day for 10 days. Blood samples were analyzed before randomization (day 0) then at days 3, 7, and 10. Clinical outcome was assessed by Sequential Organ Failure Assessment (SOFA) score. Hospital-acquired pneumonia including ventilator-associated pneumonia (VAP), adverse events, and other safety parameters were monitored as secondary endpoints.
resultsSOFA score decreased significantly in the selenite group at day 10 (1.3 ± 1.2 versus 4.6 ± 2.0, p = 0.0001). Early VAP rate was lower in the selenite group (6.7% versus 37.5%, p = 0.04), and hospital-acquired pneumonia was lower after ICU discharge (p = 0.03). Glutathione peroxidase-3 (GPx-3) activity increased in both groups, reaching a maximum at day 7 (0.62 ± 0.24 versus 0.28 ± 0.14 U/mL, p = 0.001) in the selenite group. No adverse events attributable to selenite were observed.
conclusionsDaily infusion of 1,600 μg Se (as selenite), following an initial bolus of 2,000 μg, is novel and without short-term adverse events. High-dose parenteral selenite significantly increases Se status, improves illness severity, and lowers incidence of hospital-acquired pneumonia including early VAP for SIRS patients in ICU.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.